Q BioMed Inc. CEO Provides Corporate Overview in an Interview With Scrip Intelligence

Mike Ward Global Director of Content, Informa Pharma Insights discusses Q BioMed with Denis Corin in San Francisco at the BioTech Showcase 2016

Feb 29, 2016, 09:45 ET from Q BioMed Inc

NEW YORK, February 29, 2016 /PRNewswire/ --

Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company is pleased to share the recently published video interview from the Biotech Showcase conference which took place in San Francisco in January 2016.

In the video, CEO Denis Corin is interviewed by Mike Ward, Chief Content Officer, Datamonitor Healthcare & Scrip Intelligence at Informa. Denis discusses the Q BioMed business strategy and recent corporate developments. Watch the interview here http://www.partnering360.com/insight/showroom/id/736

We invite our shareholders and interested parties to subscribe to our email list and stay informed on our website at http://www.qbiomed.com and follow us on the social media feeds we use.

About Q BioMed Inc. 

Q BioMed Inc. "Q" is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

Forward-Looking Statements: 

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Denis Corin
Q BioMed Inc.